SE
MCID: STT001
MIFTS: 58

Status Epilepticus (SE)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Status Epilepticus

MalaCards integrated aliases for Status Epilepticus:

Name: Status Epilepticus 12 20 29 54 6 44 15 17 70 32
Grand Mal Status Epilepticus 70 32
Generalized Convulsive Status Epilepticus 20
Grand Mal Status 12
Gcse 20
Se 20

Classifications:



External Ids:

Disease Ontology 12 DOID:1824
MeSH 44 D013226
NCIt 50 C85079
SNOMED-CT 67 155039002
ICD10 32 G41 G41.0 G41.9
UMLS 70 C0038220 C0311335

Summaries for Status Epilepticus

MalaCards based summary : Status Epilepticus, also known as grand mal status epilepticus, is related to febrile infection-related epilepsy syndrome and lennox-gastaut syndrome, and has symptoms including seizures and symptomatic seizures. An important gene associated with Status Epilepticus is GALC (Galactosylceramidase), and among its related pathways/superpathways are Circadian entrainment and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Phenytoin and Clonazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 73 Status epilepticus (SE) is a single seizure lasting more than five minutes or two or more seizures... more...

Related Diseases for Status Epilepticus

Diseases related to Status Epilepticus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 839)
# Related Disease Score Top Affiliating Genes
1 febrile infection-related epilepsy syndrome 33.3 SCN1A POLG PCDH19
2 lennox-gastaut syndrome 32.4 SCN1A POLG PCDH19 GRIN2B
3 dravet syndrome 32.3 SCN1A PVALB PCDH19 LGI1 GRIN2B
4 seizure disorder 32.1 SCN1A POLG PCDH19 GALC
5 temporal lobe epilepsy 31.4 PVALB NTRK2 NPY LGI1 GRIN2B GFAP
6 early myoclonic encephalopathy 31.4 SCN1A POLG PCDH19 LGI1
7 limbic encephalitis 31.3 LGI1 GRIN2B GRIA1
8 creutzfeldt-jakob disease 31.2 PVALB GFAP ENO2 BDNF
9 brain injury 31.2 GFAP ENO2 BDNF
10 landau-kleffner syndrome 31.2 SCN1A PCDH19 GRIN2B
11 epilepsy, myoclonic juvenile 31.1 SCN1A PVALB PCDH19 LGI1
12 traumatic brain injury 31.1 GFAP ENO2 BDNF
13 epilepsy, idiopathic generalized 31.1 SCN1A PVALB POLG PCDH19 LGI1
14 epilepsy 31.0 SCN1A PVALB POLG PCDH19 NPY LGI1
15 encephalomalacia 30.9 GFAP GALC BDNF
16 amnestic disorder 30.8 LGI1 GRIN2B GRIA1 FOS BDNF
17 west syndrome 30.8 SCN1A PVALB PCDH19 NTRK2 LGI1 GRIN2B
18 dystonia 30.7 PVALB POLG NPY GRIN2B BDNF
19 childhood absence epilepsy 30.6 SCN1A PVALB PCDH19 LGI1 FOS
20 depression 30.5 GRIA2 GRIA1 BDNF
21 benign epilepsy with centrotemporal spikes 30.5 SCN1A PCDH19 LGI1 GRIN2B BDNF
22 withdrawal disorder 30.5 NPY GRIN2B FOS
23 migraine with or without aura 1 30.5 SCN1A POLG NPY GRIN2B GRIA1 FOS
24 anxiety 30.5 NTRK2 NPY GRIN2B GRIA1 BDNF
25 choreatic disease 30.4 PVALB LGI1 GRIN2B BDNF
26 anterograde amnesia 30.4 LGI1 GRIN2B FOS BDNF
27 ganglioglioma 30.4 PVALB NTRK2 GFAP ENO2
28 speech and communication disorders 30.4 LGI1 GRIN2B GFAP BDNF
29 generalized epilepsy with febrile seizures plus 30.4 SCN1A PVALB PCDH19 LGI1
30 speech disorder 30.3 PVALB GRIN2B CALB1
31 mental depression 30.3 NTRK2 GRIN2B GRIA1 BDNF
32 cortical deafness 30.3 LGI1 BDNF
33 toxic encephalopathy 30.2 NTRK2 JUN GRIN2B GRIA1 GFAP BDNF
34 neonatal hypoxic and ischemic brain injury 30.2 PVALB ENO2 BDNF
35 fragile x syndrome 30.2 PVALB NTRK2 GRIN2B GRIA2 GRIA1 BDNF
36 psychotic disorder 30.2 PVALB GRIN2B GRIA1 BDNF
37 sleep disorder 30.2 NPY GRIN2B FOS BDNF
38 reflex epilepsy 30.2 SCN1A LGI1
39 stuttering 30.2 PVALB NPY CALB1
40 paroxysmal dystonia 30.2 PVALB NPY GRIN2B
41 attention deficit-hyperactivity disorder 30.1 NTRK2 NPY GRIN2B FOS BDNF
42 bipolar disorder 30.1 PVALB POLG NTRK2 GRIN2B GRIA2 GRIA1
43 alzheimer disease 30.0 PVALB NTRK2 GRIN2B GRIA2 GRIA1 GFAP
44 optic nerve disease 30.0 POLG LGI1 JUN GFAP BDNF
45 alcohol dependence 30.0 NTRK2 NPY GRIN2B GABRA4 BDNF
46 obsessive-compulsive disorder 29.9 NTRK2 NPY GRIN2B GRIA2 BDNF
47 retrograde amnesia 29.9 LGI1 GRIN2B GRIA2 GRIA1 FOS BDNF
48 dissociative disorder 29.9 GRIN2B BDNF
49 major depressive disorder 29.7 PVALB NTRK2 NPY GRIN2B GRIA2 GRIA1
50 peripheral nervous system disease 29.6 POLG NTRK2 NPY JUN GFAP GAP43

Comorbidity relations with Status Epilepticus via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Alzheimer Disease
Bronchitis Cerebral Atherosclerosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Status Epilepticus:



Diseases related to Status Epilepticus

Symptoms & Phenotypes for Status Epilepticus

UMLS symptoms related to Status Epilepticus:


seizures; symptomatic seizures

MGI Mouse Phenotypes related to Status Epilepticus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF CALB1 ENO2 FOS GABRA4 GALC
2 nervous system MP:0003631 10.26 BDNF CALB1 ENO2 FOS GABRA4 GALC
3 growth/size/body region MP:0005378 10.24 BDNF ENO2 FOS GALC GAP43 GFAP
4 cellular MP:0005384 10.18 BDNF ENO2 FOS GALC GAP43 GFAP
5 mortality/aging MP:0010768 10.17 BDNF FOS GALC GAP43 GFAP GRIA2
6 no phenotypic analysis MP:0003012 9.76 BDNF GABRA4 GRIA1 GRIA2 GRIN2B JUN
7 normal MP:0002873 9.73 BDNF CALB1 FOS GABRA4 GFAP GRIA1
8 vision/eye MP:0005391 9.28 BDNF FOS GALC GAP43 GFAP JUN

Drugs & Therapeutics for Status Epilepticus

Drugs for Status Epilepticus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2
Clonazepam Approved, Illicit Phase 3 1622-61-3 2802
3
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
4
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
5
Paraldehyde Approved, Investigational Phase 3 123-63-7 31264
6
gamma-Aminobutyric acid Approved, Investigational Phase 2, Phase 3 56-12-2 119
7
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 439-14-5 3016
8
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
9
Thiopental Approved, Vet_approved Phase 3 76-75-5 3000715
10
Pentobarbital Approved, Investigational, Vet_approved Phase 3 76-74-4 4737
11
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
12
Glutamic acid Approved, Nutraceutical Phase 2, Phase 3 56-86-0 33032
13
Aspartic acid Approved, Nutraceutical Phase 2, Phase 3 56-84-8 5960
14 Pharmaceutical Solutions Phase 3
15 N-Methylaspartate Phase 2, Phase 3
16 Psychotropic Drugs Phase 3
17 Gastrointestinal Agents Phase 3
18 Antiemetics Phase 3
19 Anti-Anxiety Agents Phase 3
20 diuretics Phase 2, Phase 3
21 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
22
Coal tar Approved Phase 1, Phase 2 8007-45-2
23
Vigabatrin Approved Phase 2 60643-86-9, 68506-86-5 5665
24
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
25
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
26
Ethanol Approved Phase 1 64-17-5 702
27 Strawberry Approved Phase 1
28 Antirheumatic Agents Phase 1
29 Immunosuppressive Agents Phase 1
30 Immunologic Factors Phase 1
31 Alkylating Agents Phase 1
32 Bendamustine Hydrochloride Phase 1
33 Epidiolex Phase 1
34
Epinephrine Approved, Vet_approved 51-43-4 5816
35
Racepinephrine Approved 329-65-7 838
36
Clobazam Approved, Illicit 22316-47-8 2789
37
Sage Approved
38
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
39 Liver Extracts
40 Epinephryl borate
41 GABA Agonists
42 Protective Agents
43 Antioxidants

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus: a Randomized Clinical Trial Recruiting NCT04176887 Phase 4 Levetiracetam Injection;Phenytoin Injection
2 Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus Recruiting NCT04829838 Phase 4 intravenous levetireacetam
3 Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Completed NCT00004297 Phase 3 diazepam;lorazepam
4 Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients Completed NCT01870024 Phase 3 Clonazepam;Fosphenytoin;Placebo;Lorazepam
5 Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus Completed NCT01150331 Phase 3 Levetiracetam/Clonazepam;Clonazepam/Placebo levetiracetam IV
6 Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial Completed NCT00735527 Phase 3 Lorazepam;Lorazepam
7 Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility Completed NCT01586208 Phase 3 valproic acid (VPA)
8 A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus Completed NCT02239380 Phase 3 Lorazepam
9 A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children Completed NCT00116064 Phase 3 intranasal lorazepam;intramuscular paraldehyde
10 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus Completed NCT02477618 Phase 3 SAGE-547;Placebo
11 Childhood Convulsive Status Epilepticus - In Search Of Optimal Drug Management In A Resource Limited Setting Completed NCT03650270 Phase 3 Phenobarbital
12 Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam Completed NCT00621478 Phase 2, Phase 3 lorazepam or diazepam
13 Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study Completed NCT01359332 Phase 3
14 A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room Completed NCT03336645 Phase 3 SHP615
15 A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus. Completed NCT01960075 Phase 3 Fosphenytoin;Levetiracetam;Valproic acid
16 A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics Completed NCT00809146 Phase 3 Intramuscular route of active treatment;Intravenous route of active treatment
17 A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings Completed NCT03336450 Phase 3 SHP615;MHOS/SHP615
18 Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study Recruiting NCT03115489 Phase 2, Phase 3 Traditional Treatment (Group T);Ketamine Infusion (Group K)
19 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus Recruiting NCT04391569 Phase 3 Ganaxolone;Placebo
20 Efficacy of add-on PEramPanel in Focal Motor Status Epilepticus Not yet recruiting NCT04309721 Phase 3 Perampanel;Placebo
21 A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus Terminated NCT00265616 Phase 3 propofol;thiopental/pentobarbital
22 Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial Terminated NCT00343096 Phase 3 Lorazepam
23 Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study. Terminated NCT02431663 Phase 3 Ketamine
24 Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS) Terminated NCT02904265 Phase 2, Phase 3 Diazepam;Acetazolamide
25 Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus Withdrawn NCT02726867 Phase 3 levetiracetam;lacosamide;Ketamine;Phenobarbital
26 Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus Unknown status NCT00362141 Phase 2 levetiracetam (add-on)
27 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
28 A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus Completed NCT03350035 Phase 2 IV Ganaxolone active;IV Placebo, non-active
29 An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Completed NCT02052739 Phase 1, Phase 2 SAGE-547
30 Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China Recruiting NCT03025906 Phase 2 Phenobarbital;Valproate
31 VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa Not yet recruiting NCT04772547 Phase 2 Vigabatrin Only Product
32 Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus Withdrawn NCT00603135 Phase 2 first-line i/v-levetiracetam
33 Use of Lorazepam for the Treatment of Status Epilepticus Completed NCT00114569 Phase 1 lorazepam
34 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
35 Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). Recruiting NCT04721691 Phase 1 Epidiolex 100 mg/mL Oral Solution
36 Phase 1, Open-Label, Comparison Study to Evaluate the Safety and Pharmacokinetics of a Single Intramuscular Administration of 10 mg Midazolam Using an Auto-Injector vs Marketed Midazolam Vials in Healthy Adults. Not yet recruiting NCT04679623 Phase 1 Seizalam
37 Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures Unknown status NCT01268904 Valproate
38 Management of Non Convulsive Status Epilepticus Unknown status NCT03245099
39 A Multi-center Clinical Study of Children With Status Epilepticus in China Unknown status NCT03378687
40 Management Strategies for Electrical Status Epilepticus During Sleep Unknown status NCT03251820 corticosteroid
41 Integrating EEG Into Acute Medicine: EEG in In-hospital Patients With Seizure or Altered Mental State Who Have Been Consulted by Medical Emergency Team Completed NCT02383745
42 Feasibility and Tolerability of the Ketogenic Diet in the Treatment of Refractory Status Epilepticus in a Neurointensive Care Unit. Completed NCT01796574
43 Diagnostic Utility of Emergency Electroencephalography in Identifying Non-convulsive Seizure and Subclinical Status Epilepticus in Patients With Altered Mental Status Completed NCT01355211
44 Randomized and Multicenter Study Assessing the Efficacy of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus. Completed NCT01791868 Intravenous Sodium Valproate;Placebo
45 Seizure Rescue Medication: Caregiver Education in a Simulation Setting Completed NCT03562351
46 EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus Completed NCT03138876 Anti-seizure medication
47 Smartphone Medical Applications to Reduce Treatment Dosage Errors in Pediatric Resuscitation; a Randomized Simulation Trial Completed NCT02958605
48 Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment Completed NCT02381977
49 Does Use of Rapid Response EEG Impact Clinical Decision Making Completed NCT03534258
50 Creation, Implementation, and Analysis of a Seizure Action Plan Completed NCT02995759

Search NIH Clinical Center for Status Epilepticus

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Amobarbital
AMOBARBITAL NA PWDR
Amobarbital Sodium
Diazepam
Etomidate
fosphenytoin
Fosphenytoin sodium
Lorazepam
Midazolam
Midazolam Hydrochloride
Pentobarbital
PENTOBARBITAL NA PWDR
Pentobarbital Sodium
Propofol

Cochrane evidence based reviews: status epilepticus

Genetic Tests for Status Epilepticus

Genetic tests related to Status Epilepticus:

# Genetic test Affiliating Genes
1 Status Epilepticus 29

Anatomical Context for Status Epilepticus

MalaCards organs/tissues related to Status Epilepticus:

40
Brain, Temporal Lobe, Cortex, Amygdala, Thalamus, Endothelial, Heart

Publications for Status Epilepticus

Articles related to Status Epilepticus:

(show top 50) (show all 12676)
# Title Authors PMID Year
1
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. 61 54
20138553 2010
2
Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. 54 61
20004712 2010
3
The unfolding clinical spectrum of POLG mutations. 54 61
19578034 2009
4
Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. 61 54
18595663 2008
5
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 54 61
18294203 2008
6
Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. 61 54
18177354 2008
7
Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. 61 54
17727632 2007
8
Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. 54 61
16901909 2006
9
Histone modifications in status epilepticus induced by kainate. 61 54
16598677 2006
10
Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. 61 54
16469864 2006
11
Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. 54 61
16091474 2005
12
Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. 61 54
15191797 2004
13
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. 61 54
14689039 2004
14
Transient downregulation of Sema3A mRNA in a rat model for temporal lobe epilepsy. A novel molecular event potentially contributing to mossy fiber sprouting. 54 61
12821384 2003
15
Serum neuron-specific enolase in children with febrile seizures: time profile and prognostic implications. 61 54
12767459 2003
16
Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures. 54 61
11166790 2001
17
Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. 54 61
10531425 1999
18
Serum neuron-specific enolase in the major subtypes of status epilepticus. 54 61
10078721 1999
19
Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. 54 61
9595992 1998
20
Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss. 54 61
9825961 1998
21
Serum NSE in status epilepticus. 61 54
8649598 1996
22
The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. 61 54
9246466 1996
23
Serum neuron-specific enolase in human status epilepticus. 61 54
7783877 1995
24
Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischaemic brain injury? 54 61
8326831 1993
25
Deletion of the Na-K-2Cl cotransporter NKCC1 results in a more severe epileptic phenotype in the intrahippocampal kainate mouse model of temporal lobe epilepsy. 61
33581254 2021
26
Alkaline brain pH shift in rodent lithium-pilocarpine model of epilepsy with chronic seizures. 61
33556378 2021
27
Prediction of AESD and neurological sequelae in febrile status epilepticus. 61
33563484 2021
28
The complement C3-C3aR pathway mediates microglia-astrocyte interaction following status epilepticus. 61
33314324 2021
29
Diisopropylfluorophosphate-induced status epilepticus drives complex glial cell phenotypes in adult male mice. 61
33529768 2021
30
An Adult Case of Hemiplegia, Aphasia, and Hemispheric Atrophy Associated with Febrile Status Epilepticus. 61
33116007 2021
31
The first national survey on practices of neurological prognostication after cardiac arrest in China, still a lot to do. 61
33098255 2021
32
Update on the management of status epilepticus. 61
33664203 2021
33
Interactions between carbapenems and valproic acid among the patients in the intensive care units. 61
33383308 2021
34
Early non-convulsive seizures are associated with the development of acute encephalopathy with biphasic seizures and late reduced diffusion. 61
33342582 2021
35
Evaluation of adenosine A1 receptor agonists as neuroprotective countermeasures against Soman intoxication in rats. 61
33631229 2021
36
Meningitis in the Setting of Frontoethmoidal and Temporal Meningoencephaloceles. 61
33791067 2021
37
HCN Channel Phosphorylation Sites Mapped by Mass Spectrometry in Human Epilepsy Patients and in an Animal Model of Temporal Lobe Epilepsy. 61
33571596 2021
38
Sporadic Creutzfeldt-Jakob disease with tau pathology mimicking new-onset refractory non-convulsive status epilepticus: Case report and review of the literature. 61
33135248 2021
39
Extent of Leptomeningeal Capillary Malformation is Associated With Severity of Epilepsy in Sturge-Weber Syndrome. 61
33677229 2021
40
Neurological complications of COVID19 during March 2020 at LCMC health university medical center: Dataset. 61
33688573 2021
41
Epidemiology of status epilepticus in a non-urban area in Switzerland. 61
33251617 2021
42
Possible Role of High-Dose Barbiturates and Early Administration of Parenteral Ketogenic Diet for Reducing Development of Chronic Epilepsy in Febrile Infection-Related Epilepsy Syndrome: A Case Report. 61
33231274 2021
43
A novel homozygous SLC13A5 whole-gene deletion generated by Alu/Alu-mediated rearrangement in an Iraqi family with epileptic encephalopathy. 61
33797191 2021
44
Roles of Very Fast Ripple (500-1000[Formula: see text]Hz) in the Hippocampal Network During Status Epilepticus. 61
33357153 2021
45
Factors associated with resistance to benzodiazepines in status epilepticus. 61
33652289 2021
46
Corrigendum to 'Heparin ameliorates cerebral edema and improves outcomes following status epilepticus by protecting endothelial glycocalyx in mice' [Exp Neurol. volume 330 (2020) 113320]. 61
33485107 2021
47
Does a combination of ≥2 abnormal tests vs. the ERC-ESICM stepwise algorithm improve prediction of poor neurological outcome after cardiac arrest? A post-hoc analysis of the ProNeCA multicentre study. 61
33338571 2021
48
The risk of cardiac mortality in patients with status epilepticus: A 10-year study using data from the Centers for Disease Control and Prevention (CDC). 61
33740495 2021
49
Does continuous electroencephalography influence therapeutic decisions in neurocritical care? 61
33091148 2021
50
Electroencephalographic Abnormalities are Common in COVID-19 and are Associated with Outcomes. 61
33704826 2021

Variations for Status Epilepticus

ClinVar genetic disease variations for Status Epilepticus:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GALC NM_000153.4(GALC):c.196G>A (p.Ala66Thr) SNV Likely pathogenic 374023 rs1057518843 GRCh37: 14:88454867-88454867
GRCh38: 14:87988523-87988523
2 GALC NM_000153.4(GALC):c.850G>A (p.Gly284Ser) SNV Likely pathogenic 374024 rs377274761 GRCh37: 14:88434737-88434737
GRCh38: 14:87968393-87968393

Expression for Status Epilepticus

Search GEO for disease gene expression data for Status Epilepticus.

Pathways for Status Epilepticus

Pathways related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 SCN1A GRIN2B GRIA2 GRIA1 FOS
2
Show member pathways
12.46 SCN1A NTRK2 GRIN2B GRIA2 GRIA1 FOS
3 12.03 NPY JUN GRIN2B GRIA2 GRIA1 FOS
4
Show member pathways
12.01 NTRK2 JUN FOS BDNF
5 11.86 SCN1A NTRK2 NPY GRIN2B GRIA2 GRIA1
6 11.81 GFAP GAP43 FOS BDNF
7
Show member pathways
11.81 JUN GRIN2B GRIA2 GRIA1 FOS BDNF
8
Show member pathways
11.67 GRIN2B GRIA2 GRIA1
9 11.66 NTRK2 JUN GRIN2B GRIA2 GRIA1 FOS
10 11.58 GFAP GALC BDNF
11 11.29 JUN FOS CALB1
12 11.27 GRIN2B GRIA2 GRIA1 GABRA4
13 10.98 GRIN2B GRIA2 GRIA1
14 10.85 NTRK2 JUN GFAP FOS BDNF
15 10.7 NTRK2 BDNF
16 10.6 JUN FOS

GO Terms for Status Epilepticus

Cellular components related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.95 NTRK2 LGI1 GRIN2B GRIA2 GRIA1 GAP43
2 neuron projection GO:0043005 9.92 GRIN2B GRIA1 GABRA4 FOS CALB1
3 postsynaptic membrane GO:0045211 9.81 GRIN2B GRIA2 GRIA1 GABRA4
4 axon GO:0030424 9.8 SCN1A PVALB NTRK2 GAP43 CALB1 BDNF
5 dendritic spine GO:0043197 9.78 NTRK2 GRIA2 GRIA1 CALB1
6 postsynaptic density GO:0014069 9.77 NTRK2 GRIN2B GRIA2 GRIA1 GAP43
7 cell body GO:0044297 9.73 GRIA1 GFAP CALB1
8 neuronal cell body GO:0043025 9.73 SCN1A PVALB GRIA2 GRIA1 ENO2 CALB1
9 GABA-ergic synapse GO:0098982 9.71 GAP43 GABRA4 CALB1
10 terminal bouton GO:0043195 9.67 POLG NTRK2 CALB1
11 postsynaptic density membrane GO:0098839 9.63 GRIN2B GRIA2 GRIA1
12 cuticular plate GO:0032437 9.55 PVALB CALB1
13 postsynapse GO:0098794 9.55 GRIA2 GRIA1 GABRA4 CALB1 BDNF
14 dendrite GO:0030425 9.5 TRAK1 NTRK2 GRIA2 GRIA1 GAP43 CALB1
15 transcription factor AP-1 complex GO:0035976 9.43 JUN FOS
16 synapse GO:0045202 9.28 NTRK2 NPY LGI1 GRIN2B GRIA2 GRIA1

Biological processes related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.85 NTRK2 LGI1 GAP43 FOS BDNF
2 long-term synaptic potentiation GO:0060291 9.5 NTRK2 GRIN2B GFAP
3 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 9.43 GRIA1 CALB1
4 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.4 NTRK2 BDNF
5 neuronal action potential propagation GO:0019227 9.37 SCN1A NTRK2
6 chemical synaptic transmission GO:0007268 9.35 NPY GRIN2B GRIA2 GRIA1 GABRA4
7 regulation of NMDA receptor activity GO:2000310 9.33 GRIN2B GRIA2 GRIA1
8 brain-derived neurotrophic factor receptor signaling pathway GO:0031547 9.26 NTRK2 BDNF
9 ionotropic glutamate receptor signaling pathway GO:0035235 8.8 GRIN2B GRIA2 GRIA1

Molecular functions related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.5 GRIN2B GRIA2 GRIA1
2 ligand-gated ion channel activity GO:0015276 9.33 GRIN2B GRIA2 GRIA1
3 AMPA glutamate receptor activity GO:0004971 9.26 GRIA2 GRIA1
4 ionotropic glutamate receptor activity GO:0004970 9.13 GRIN2B GRIA2 GRIA1
5 ion channel activity GO:0005216 9.02 SCN1A GRIN2B GRIA2 GRIA1 GABRA4

Sources for Status Epilepticus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....